Top Story
Health EquityIn April 2022, the FDA mandated that all Phase 3 and pivotal studies include a Diversity Action Plan (DAP) to ensure the representation of historically underrepresented populations in clinical trials. This requirement, codified in the Food and Drug Omnibus Reform Act of 2022, emphasizes the need [...]
Latest Stories
Artificial Intelligence
Advertisement
Featured Webinars
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
Tuesday, December 5, 2023
Sponsor: ICON
This webinar delves into the dynamic landscape of COAs, examining their historical use and significance, current uses and best practices, and [...]
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
Friday, November 10, 2023
Sponsor: OpenHealth
This panel discusses several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.
Cell & Gene Therapies – Beginning with the End in Mind
Thursday, November 2, 2023
Sponsor: Magnolia Market Access
This webinar discusses how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful [...]
Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases
Thursday, October 12, 2023
Sponsor: Inspire
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to [...]
Handpicked Promotions & Highlights
Search HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
Latest From Our Blog
01November 2023
29October 2023
16October 2023
11October 2023
